Letizia Canziani

Dr. Letizia Canziani

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 July 2021 in Nanomaterials
Verified
Journal Article
Open access
PDF file
MMManuela Marenco
Manuela Marenco
LCLetizia Canziani
Letizia Canziani
GMGianluca De Matteis
Gianluca De Matteis
GCGiorgio Cavenaghi
Giorgio Cavenaghi
Carlo AprileCarlo Aprile
Carlo Aprile
LLLorenzo Lodola
Lorenzo Lodola
Nanoparticles of Human Serum Albumin (NC) labelled with 99mTc are widely used in Nuclear Medicine and represent the gold-standard for the intraoperative detection of the sentinel lymph node in many kinds of cancer, mainly breast cancer and melanoma. A significant amount of radionuclides can be incorporated into the HSA particle, due to the multiple binding sites, and HSA-based nanocolloid catabolism is a fast and easy process that results in innocuous degradation products. NCs labelled with different isotopes represent an interesting radiopharmaceutical for extending diagnostic accuracy and surgical outcome, but the knowledge of the chemical bond between NCs and isotopes has not been fully elucidated, including information on its strength and specificity. The aim of this study is to investigate and compare the physicochemical characteristics of the bond between NCs and 99mTc and 68Ga isotopes. Commercial kits of HSA-based nanocolloid particles (NanoAlbumon®) were used. For this purpose, we have primarily studied the kinetic orders of NC radiolabelling. Langmuir isotherms and pH effect on radiolabelling were tested and the stability of the radiometal complex was verified through competition reactions carried out in presence of different ligands. The future goal of our research is the development of inexpensive and instant kits, easily labelled with a wide spectrum of diagnostic and therapeutic isotopes, thus facilitating the availability of versatile and multipurpose radiopharmaceuticals.

9 January 2022 in Molecules
Verified
Journal Article
Open access
PDF file
LCLetizia Canziani
Letizia Canziani
MMManuela Marenco
Manuela Marenco
GCGiorgio Cavenaghi
Giorgio Cavenaghi
GMGiulia Manfrinato
Giulia Manfrinato
Angelo TagliettiAngelo Taglietti
Angelo Taglietti
LLLorenzo Lodola
Lorenzo Lodola
Background: Macroaggregated human serum albumin (MAA) properties are widely used in nuclear medicine, labelled with 99mTc. The aim of this study is to improve the knowledge about the morphology, size, dimension and physical–chemical characteristics of MAA and their bond with 99mTc and 68Ga. Methods: Commercial kits of MAA (Pulmocis®) were used. Characterisation through experiments based on SEM, DLS and Stokes’ Law were carried out. In vitro experiments for Langmuir isotherms and pH studies on radiolabelling were performed and the stability of the radiometal complex was verified through competition reactions. Results: The study settles the MAA dimension within the range 43–51 μm. The Langmuir isotherm reveals for [99mTc]MAA: Bmax (46.32), h (2.36); for [68Ga]MAA: Bmax (44.54), h (0.893). Dual labelling reveals that MAA does not discriminate different radioisotopes. Experiments on pH placed the optimal pH for labelling with 99mTc at 6. Conclusion: Radiolabelling of MAA is possible with high efficiency. The nondiscriminatory MAA bonds make this drug suitable for radiolabelling with different radioisotopes or for dual labelling. This finding illustrates the need to continue investigating MAA chemical and physical characteristics to allow for secure labelling with different isotopes.

29 June 2026 in Nuclear Technology
Verified
Journal Article
Open access
LCLetizia Canziani
Letizia Canziani
MFMaria Fabiano
Maria Fabiano
GGGiorgio Grosso
Giorgio Grosso
GGGiulia Gambini
Giulia Gambini
AGAndrea Gandini
Andrea Gandini
ASAndrea Salvini
Andrea Salvini

Verified
Journal Article
Open access
PDF file
Carlo AprileCarlo Aprile
Carlo Aprile
OGOnelio Geatti
Onelio Geatti
LCLetizia Canziani
Letizia Canziani
LLLorenzo Lodola
Lorenzo Lodola
Targeted radionuclide therapy (TRT) is gaining wide and rapid acceptance in clinical practice as it can deliver alpha or beta irradiation to a tumor-associated target which may be present in the tumor cell itself or in the microenvironment